These findings suggest that targeting the SNORA47-EBF3/RPL11/c-Myc axis is a useful strategy to influence chemotherapy sensitivity and to ascertain potential therapeutic targets for the enhancement of treatment efficacy in breast cancer. This evidence concerns the gene EBF3 and breast carcinoma.